Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings

Pharmacielo schedules AGM, plans debt settlement

By The Northwire Desk — AI Analysis Feb 17, 2026 · 19:49 PCLO · 0.065 Pharmacielo Ltd
PCLO · Price

Executive Summary

  • Pharmacielo Ltd. announced its intention to issue 12,153,937 common shares to settle $972,317.12 in accrued semi-annual interest payments on its 11% secured debentures.
  • The issuance is subject to approval by the TSX Venture Exchange and sets the record date for the upcoming Annual General Meeting (AGM) for April 2, 2026.
  • The effective price per share is eight cents, calculated based on the terms of the debentures and TSX Venture Exchange Policy 4.3.

Key Details

  • Share Issuance: 12,153,937 common shares of Pharmacielo Ltd.
  • Purpose: Satisfaction of aggregate accrued semi-annual interest payments totaling $972,317.12.
  • Debenture Terms: 11% secured debentures.
  • Effective Price: $0.08 per interest share.
  • Regulatory Approval: Subject to approval by the TSX Venture Exchange.
  • Compliance: Calculation determined in accordance with debenture terms and TSX Venture Exchange Policy 4.3, Section 3.3.
  • Hold Period: Shares are subject to any applicable statutory hold period under Canadian securities laws.
  • AGM Details:
    • Date: April 2, 2026.
    • Record Date: February 23, 2026.
    • Materials: To be filed on SEDAR+.

Notable Quotes

  • No direct quotes from management were included in the provided text.
Read the original news release →

More from Pharmacielo Ltd

May 19, 2026 · 07:31

PharmaCielo Settles Debt Interest with Equity Amidst Liquidity Concerns

Other Apr 17, 2026 · 07:31

PharmaCielo Dilutes Shareholders to Service Debt as Principal Maturity Looms

Other Mar 17, 2026 · 07:31

PharmaCielo Announces the Issuance of Interest Shares

Financings Mar 02, 2026 · 07:31

PharmaCielo Announces 2025 Q3 Results, AGM Details

Earnings Feb 17, 2026 · 07:46

PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares

Financings Dec 30, 2025 · 12:53

Pharmacielo cease trade order revoked by OSC

Regulatory